CHRS
Price
$1.50
Change
+$0.05 (+3.45%)
Updated
Sep 26 closing price
Capitalization
174.34M
44 days until earnings call
DNA
Price
$11.50
Change
+$0.25 (+2.22%)
Updated
Sep 26 closing price
Capitalization
680.8M
Interact to see
Advertisement

CHRS vs DNA

Header iconCHRS vs DNA Comparison
Open Charts CHRS vs DNABanner chart's image
Coherus Oncology
Price$1.50
Change+$0.05 (+3.45%)
Volume$1.57M
Capitalization174.34M
Ginkgo Bioworks Holdings
Price$11.50
Change+$0.25 (+2.22%)
Volume$1.05M
Capitalization680.8M
CHRS vs DNA Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. DNA commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and DNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CHRS: $1.50 vs. DNA: $11.50)
Brand notoriety: CHRS and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 110% vs. DNA: 66%
Market capitalization -- CHRS: $174.34M vs. DNA: $680.8M
CHRS [@Biotechnology] is valued at $174.34M. DNA’s [@Biotechnology] market capitalization is $680.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, CHRS is a better buy in the long-term than DNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while DNA’s TA Score has 3 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 4 bearish.
  • DNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than DNA.

Price Growth

CHRS (@Biotechnology) experienced а -6.83% price change this week, while DNA (@Biotechnology) price change was +1.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($681M) has a higher market cap than CHRS($174M). DNA YTD gains are higher at: 17.108 vs. CHRS (8.696). CHRS has higher annual earnings (EBITDA): 88.2M vs. DNA (-292.97M). DNA has more cash in the bank: 474M vs. CHRS (238M). CHRS has less debt than DNA: CHRS (41M) vs DNA (429M). CHRS has higher revenues than DNA: CHRS (272M) vs DNA (231M).
CHRSDNACHRS / DNA
Capitalization174M681M26%
EBITDA88.2M-292.97M-30%
Gain YTD8.69617.10851%
P/E Ratio2.83N/A-
Revenue272M231M118%
Total Cash238M474M50%
Total Debt41M429M10%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
5
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
84
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSDNA
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVXAX68.770.69
+1.01%
Smead International Value A
PRPPX15.880.09
+0.57%
Principal International Equity R3
FKICX6.14N/A
N/A
Fidelity Small Cap Stock K6
FMPEX28.44N/A
N/A
Fidelity Advisor Mid Cap Value C
MXLSX39.41N/A
N/A
Empower Small Cap Value Inv

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+3.45%
XENE - CHRS
40%
Loosely correlated
+4.00%
XNCR - CHRS
37%
Loosely correlated
+12.00%
RXRX - CHRS
34%
Loosely correlated
+1.94%
DNA - CHRS
34%
Loosely correlated
+2.22%
SRRK - CHRS
33%
Loosely correlated
+12.35%
More

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with RXRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
+2.22%
RXRX - DNA
51%
Loosely correlated
+1.94%
ABCL - DNA
49%
Loosely correlated
+1.94%
CRSP - DNA
47%
Loosely correlated
+2.24%
ABSI - DNA
47%
Loosely correlated
+3.02%
NTLA - DNA
45%
Loosely correlated
-1.81%
More